Extended Interval Dosing of Ocrelizumab in Patients with Multiple Sclerosis Is Not Associated with Meaningful Differences in Disease Activity

被引：0
|
作者：
Rjeily, N. Bou [1 ]
Fitzgerald, K. C. [1 ]
Mowry, E. M. [1 ]
机构：
[1] Johns Hopkins Univ, Neurol, Baltimore, MD USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2023年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P164
引用
下载
收藏
页码：95 / 95
页数：1
相关论文
共 50 条
  • [1] Extended interval dosing of ocrelizumab in patients with multiple sclerosis is not associated with meaningful differences in disease activity
    Rjeily, Nicole Bou
    Fitzgerald, Kathryn C.
    Mowry, Ellen M.
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (02) : 257 - 260
  • [2] Extended Interval Dosing of Ocrelizumab in Patients with Multiple Sclerosis Is Not Associated with Meaningful Differences in Disease Activity
    Rjeily, Nicole Bou
    Fitzgerald, Kathryn
    Mowry, Ellen
    NEUROLOGY, 2023, 100 (17)
  • [3] Extended interval dosing with ocrelizumab in multiple sclerosis
    Novak, Frederik
    Bajwa, Hamza Mahmood
    Ostergaard, Kamilla
    Berg, Jonas Munksgaard
    Madsen, Jonna Skov
    Olsen, Dorte Aalund
    Urbonaviciute, Inga
    Illes, Zsolt
    Stilund, Morten Leif
    Christensen, Jeppe Romme
    Bramow, Stephan
    Sellebjerg, Finn
    Sejbaek, Tobias
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (07) : 847 - 856
  • [4] Impact of extended interval dosing of ocrelizumab on immunoglobulin levels in multiple sclerosis
    Schuckmann, Aaron
    Steffen, Falk
    Zipp, Frauke
    Bittner, Stefan
    Pape, Katrin
    MED, 2023, 4 (06): : 361 - +
  • [5] Impact of extended interval dosing of ocrelizumab on immunoglobulin levels in multiple sclerosis
    Schuckmann, A.
    Steffen, F.
    Zipp, F.
    Bittner, S.
    Pape, K.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 655 - 655
  • [6] Control of disease activity with large extended-interval dosing of rituximab/ocrelizumab in highly active pediatric multiple sclerosis
    Venet, Melany
    Lepine, Anne
    Maarouf, Adil
    Biotti, Damien
    Boutiere, Clemence
    Casez, Olivier
    Cohen, Mikael
    Durozard, Pierre
    Demortiere, Sarah
    Giorgi, Laetitia
    Maillart, Elisabeth
    Mathey, Guillaume
    Mazzola, Laure
    Rico, Audrey
    Camdessanche, Jean-Philippe
    Deiva, Kumaran
    Pelletier, Jean
    Audoin, Bertrand
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (02) : 261 - 265
  • [7] Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19
    Rolfes, Leoni
    Pawlitzki, Marc
    Pfeuffer, Steffen
    Nelke, Christopher
    Lux, Anke
    Pul, Refik
    Kleinschnitz, Christoph
    Kleinschnitz, Konstanze
    Rogall, Rebeca
    Pape, Katrin
    Bittner, Stefan
    Zipp, Frauke
    Warnke, Clemens
    Goereci, Yasemin
    Schroeter, Michael
    Ingwersen, Jens
    Aktas, Orhan
    Klotz, Luisa
    Ruck, Tobias
    Wiendl, Heinz
    Meuth, Sven G.
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2021, 8 (05):
  • [8] Ocrelizumab Extended Interval Dosing in Primary Progressive Multiple Sclerosis: An Italian Experience
    Zanghi, Aurora
    Ferraro, Diana
    Callari, Graziella
    Valentino, Paola
    Granella, Franco
    Patti, Francesco
    Lus, Giacomo
    Bonavita, Simona
    Moretti, Maria Claudia
    Avolio, Carlo
    D'Amico, Emanuele
    CURRENT NEUROPHARMACOLOGY, 2024, 22 (02) : 339 - 345
  • [9] Memory B cell-guided extended interval dosing of ocrelizumab in multiple sclerosis
    Meng, Delania
    Sacco, Rosaria
    Disanto, Giulio
    Widmer, Fausto
    Jacober, Sarah Lena Susanna
    Gobbi, Claudio
    Zecca, Chiara
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (07) : 857 - 867
  • [10] Extended interval dosing strategies in multiple sclerosis: insights from natalizumab and ocrelizumab trials
    Yasmin Zid
    Neil P. Robertson
    Journal of Neurology, 2024, 271 : 2141 - 2143
12345